Oleiferasaponin A₂, a Novel Saponin from Camellia oleifera Abel. Seeds, Inhibits Lipid Accumulation of HepG2 Cells Through Regulating Fatty Acid Metabolism

A new triterpenoid saponin, named oleiferasaponin A₂, was isolated and identified from defatted seeds. Oleiferasaponin A₂ exhibited anti-hyperlipidemic activity on HepG2 cell lines. Further study of the hypolipidemic mechanism showed that oleiferasaponin A₂ inhibited fatty acid synthesis by signific...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 23; no. 12; p. 3296
Main Authors Di, Tai-Mei, Yang, Shao-Lan, Du, Feng-Yu, Zhao, Lei, Li, Xiao-Han, Xia, Tao, Zhang, Xin-Fu
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 12.12.2018
MDPI
Subjects
Camellia oleifera
Cell lines
Cytotoxicity
fatty acid metabolism
Fatty acids
Hyperlipidemia
hypolipidemic activity
Lipids
Liver cancer
Metabolism
NMR
Nuclear magnetic resonance
oleiferasaponin A2
Oxidation
Proteins
Saponins
Sterol regulatory element-binding protein
triterpenoid saponin
United States > US
China
oleiferasaponin A2
Camellia oleifera
triterpenoid saponin
hypolipidemic activity
fatty acid metabolism
Online AccessGet full text

Cover

More Information
Summary:A new triterpenoid saponin, named oleiferasaponin A₂, was isolated and identified from defatted seeds. Oleiferasaponin A₂ exhibited anti-hyperlipidemic activity on HepG2 cell lines. Further study of the hypolipidemic mechanism showed that oleiferasaponin A₂ inhibited fatty acid synthesis by significantly down-regulating the expression of and FAS protein, while dramatically promoting fatty acid β-oxidation by up-regulating the expression of and ACOX-1 protein. Our results demonstrate that the oleiferasaponin A₂ possesses potential medicinal value for hyperlipidemia treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules23123296